NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Easier injections for blinding eye diseases? new syringe study begins
Disease control Not yet recruitingThis study tests whether a new prefilled syringe for the drug SCD411 (a proposed biosimilar to Eylea) is easy and safe for eye doctors to use. About 33 doctors will use the syringe to treat patients with wet age-related macular degeneration, retinal vein occlusion, diabetic macul…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Sam Chun Dang Pharm. Co. Ltd. • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
New eye injection aims to control wet AMD with fewer doses
Disease control Not yet recruitingThis early-stage study tests the safety of an experimental drug called EYC-0305 in 30 adults aged 50 and older with wet age-related macular degeneration (AMD). Participants receive an injection into the eye every 24 weeks. The goal is to see if the drug is safe and tolerable, and…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Eyconis INC. • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New eye injection could mean fewer treatments for wet AMD
Disease control Not yet recruitingThis study tests a new medicine called AIV007 for people with wet age-related macular degeneration, a condition that causes vision loss. About 35 participants will receive either AIV007 or the standard treatment Eylea. The goal is to see if AIV007 can improve vision and reduce th…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: AiViva BioPharma, Inc. • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New study aims to keep patients from missing Sight-Saving eye injections
Disease control Not yet recruitingThis study tests whether a personalized care plan helps people with chronic macular diseases (like wet age-related macular degeneration or diabetic macular edema) attend their regular eye injections. Many patients skip appointments, risking vision loss. The study will enroll 200 …
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: Singapore Eye Research Institute • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
AI eye doctor: QiLin system aims to sharpen injection decisions
Knowledge-focused Not yet recruitingThis study tests an artificial intelligence system called QiLin that helps doctors decide when to give anti-VEGF injections for retinal diseases like wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. About 200 patients who have completed in…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated May 26, 2026 11:32 UTC